Clinical Trial

Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn if mirikizumab works to treat pouch disorders in adults. The main questions it aims to answer are: Does mirikizumab reduce symptoms of pouch disorders Participants will: Take mirikizumab every 4 weeks for one year Visit the clinic once every month for two months and at the end of the study Keep a diary of their symptoms
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-03-03; most recent amendment 2026-01-29.
Status change: Not Yet Recruiting → Recruiting 2025-06-17
Trial Details
NCT Number NCT06864403
Lead Sponsor University of North Carolina, Chapel Hill
Collaborators: Eli Lilly and Company
Conditions Pouchitis, Pouches, Ileoanal, Pouch, Ileal
Enrollment 25 participants
Start Date 2025-08-12
Primary Completion 2027-04 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2026-01-30